,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'bcsm', 'breast', 'destiny-breast04']
what will the late-breaking data from destiny-breast04, presented at #asco22, mean in clinical practice? stay tuned for 's take on the data on t-dxd in her2-low mbc.
keep an on your inbox next week for the cor2ed update from asco! #breastcancer #meded #bcsm 
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally. #COR2ED #MedEd #IME